Compare AbCellera Biologics Inc (ABCL) vs Dover Corp (DOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Dover Corp — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Dover Corp trades at $211.06 (market cap $28.82B). The key difference: Dover Corp is far larger — about 12.3× AbCellera Biologics Inc's market cap, and Dover Corp pays a 0.97% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DOV | |
|---|---|---|
Market Cap | $2.35B | $28.82B |
Sector | Health | Industrials |
52-Week High | $8.12 | $233.31 |
52-Week Low | $2.78 | $161.16 |
Enterprise Value | $1.99B | $30.47B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Dover Corporation (DOV) trades at $214.05, up 0.16% on the day, with a bearish technical signal but strong fundamentals including a 13.3% net income margin and consistent earnings beats. Recent news highlights AI data center demand tailwinds and product launches across its subsidiaries. The stock shows healthy profitability with ROE at 15.06% and a P/E of 26.84, while analyst consensus is bullish with a $251 price target.
Outlook remains positive driven by earnings momentum and AI-related growth, though technical weakness and market volatility pose near-term risks. The stock offers value with a 17% upside to consensus target, supported by dividend payments and institutional confidence, but investors should monitor execution on data center opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
